Description
Book SynopsisNew ways of understanding the brain – its nature, its capacities, its function, and its dysfunction – hold great promise for human wellbeing. Novel therapeutics spurred by this understanding have important roles addressing many clinical conditions, including Alzheimer Disease, depression, addiction, and obsessive-compulsive disorder. This unique title explores a wide range of groundbreaking sciences and clinical practices for brain-based conditions, including deep brain stimulation, optogenetics, technology-delivered therapies, predictive testing, and new clinical uses of ketamine, cannabis, and other psychoactive substances.
An introduction to the imperative to develop new treatments for devastating brain disorders and the state of current therapeutics in psychiatry, addiction, and behavioral disorders is presented, and chapters from leading physician-scientists and neuroethicists outline the clinical and the ethical issues arising in innovation and in the creation of new therapeutics for brain diseases. Written by renowned thought leaders in their fields, the book presents tightly written contributions on novel qualitative and quantitative data from stakeholders in the field, including neuroscientist-clinicians, people living with mental illness and/or addictions, and oversight/policy stakeholders.
Concise, anticipatory, and centered on the principles governing human biomedical research and innovation in developing novel therapeutics for brain disorders, Ethics and Clinical Neuroinnovation will be of great value to clinicians, researchers, and students from a vast array of backgrounds, including neuroethics, neuroscience, psychology, psychiatry, philosophy, entrepreneurship, and the law.
Table of ContentsSection 1: Fundamentals: the imperative for novel clinical therapeutics for mental disorders
Chapter 1: The case for neuroinnovation: Health burdens associated with psychiatric, addiction-related, and co-occurring disorders
Chapter 02: Neuroinnovation in medicine: History and future
Chapter 03: Clinical neuroinnovation: Ethical frameworks and emerging issues
Chapter 04: Changing contexts of neuroinnovation: Societal considerations
Chapter 05: Changing contexts of neuroinnovation: Societal considerations
Chapter 06: The NIH’s BRAIN2025 agenda: Attention to related ethical considerations
Section 2: Special Topics in Clinical Neuroinnovation
Chapter 07: In the surgical suite: Neurosurgery and neuroinnovation, and the ethics of neurostimulation for severe obesity
Chapter 08: In the midst of uncertainty: Neuroinnovation at the edge of consciousness
Chapter 09: On the edges: The ethics of human studies with psychedelic substances
Chapter 10: In the courts: Emerging neuroscience technologies used for forensic purposes: ethical and legal implications
Chapter 11: Into the wild: A comment on neuroethics startups - Moving from lab to society
Section 3: Neuroethics and Innovation: Inquiry informed by the Roberts Valence Model
Chapter 12: Introduction to our project: Understanding ethically-salient perspectives of diverse societal stakeholders in innovative neuroscience research on mental disorders
Chapter 13: Qualitative phase: Codebook development
Chapter 14: Qualitative findings: Diverse stakeholder perspectives on ethical considerations in innovative neuroscience research involving human volunteers
Chapter 15: Qualitative findings: A focus on professional stakeholder perspectives on the environments and challenges of innovative neuroscience research
Chapter 16: Qualitative findings: A focus on professional stakeholder perspectives on additional issues in research and clinical innovation in the brain
Chapter 17: Pilot quantitative phase: Amazon MTurk as a novel approach to stakeholder-based neuroethics survey research
